Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05801029
What this trial is testing

Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Not applicableStudy completedNCT01106781
What this trial is testing

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 591
Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Early research (Phase 1)Study completedNCT01999985
What this trial is testing

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Lung CancerNon-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute 25
Testing effectiveness (Phase 2)Study completedNCT01897480
What this trial is testing

LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 168
Not applicableStudy completedNCT01185314
What this trial is testing

To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 1,270
Testing effectiveness (Phase 2)Study completedNCT06521034
What this trial is testing

First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationEGFR-TKI Sensitizing Mutation
Yongchang Zhang 124
Testing effectiveness (Phase 2)Study completedNCT01469000
What this trial is testing

Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non Small Cell Lung
Eli Lilly and Company 195
Testing effectiveness (Phase 2)Study completedNCT02264210
What this trial is testing

Icotinib for Completed Resected IB NSCLC With EGFR Mutation

Who this might be right for
Lung NeoplasmsSquamous Cell Lung CancerAdenocarcinoma of the Lung+4 more
Sun Yat-sen University 128
Not applicableWithdrawnNCT06075615
What this trial is testing

Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer
Not applicableStudy completedNCT01255150
What this trial is testing

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Carcinoma
National Cancer Institute (NCI) 15
Large-scale testing (Phase 3)Active Not RecruitingNCT04988295
What this trial is testing

Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 776
Large-scale testing (Phase 3)Study completedNCT01544179
What this trial is testing

IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 265
Testing effectiveness (Phase 2)Active Not RecruitingNCT03769103
What this trial is testing

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

Who this might be right for
Lung Cancer Non-small Cell Stage IVBrain Metastases
British Columbia Cancer Agency 40
Testing effectiveness (Phase 2)Study completedNCT03049618
What this trial is testing

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Who this might be right for
ALK Gene MutationBRAF Gene MutationEGFR Gene Mutation+9 more
University of Southern California 42
Testing effectiveness (Phase 2)Study completedNCT00891579
What this trial is testing

Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non Small Cell Lung Cancer
Chinese Society of Lung Cancer 161
Not applicableStudy completedNCT02418234
What this trial is testing

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic
First People's Hospital of Hangzhou 314
Not applicableApproved For MarketingNCT04535557
What this trial is testing

An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Millennium Pharmaceuticals, Inc.
Early research (Phase 1)Study completedNCT02374645
What this trial is testing

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Hutchison Medipharma Limited 64
Testing effectiveness (Phase 2)Study completedNCT01802632
What this trial is testing

AZD9291 First Time In Patients Ascending Dose Study

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 603
Next Page